Capricor Therapeutics
CAPR
#7991
Rank
โ‚ฌ0.24 B
Marketcap
5,44ย โ‚ฌ
Share price
-4.36%
Change (1 day)
-61.47%
Change (1 year)

Revenue for Capricor Therapeutics (CAPR)

Revenue in 2025 (TTM): โ‚ฌ10.69 Million

According to Capricor Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ9.51 Million. In 2024 the company made a revenue of โ‚ฌ21.4 Million a decrease over the revenue in the year 2023 that were of โ‚ฌ22.77 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Capricor Therapeutics from 2009 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ10.69 M-50.02%
2024 โ‚ฌ21.4 M-6.04%
2023 โ‚ฌ22.77 M857.54%
2022 โ‚ฌ2.37 M999.96%
2021 โ‚ฌ0.21 M-14.27%
2020 โ‚ฌ0.25 M-71.88%
2019 โ‚ฌ0.89 M-38.59%
2018 โ‚ฌ1.46 M-19.98%
2017 โ‚ฌ1.82 M-39.8%
2016 โ‚ฌ3.03 M-12.18%
2015 โ‚ฌ3.45 M0.8%
2014 โ‚ฌ3.42 M
2013 N/A-100%
2012 โ‚ฌ0.14 M-85.83%
2011 โ‚ฌ1.04 M
2010 N/A
2009 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Cytokinetics
CYTK
โ‚ฌ74.59 M 683.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚ฌ78.81 B 827,795.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ2.29 B 24,002.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚ฌ2.22 M-76.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Eterna Therapeutics
ERNA
โ‚ฌ0 M-99.99%๐Ÿ‡บ๐Ÿ‡ธ USA